Streetbeat News

Analyst Ratings

CPB

RBC Capital analyst Nik Modi has reiterated a 'Sector Perform' rating on Campbell Soup (NYSE:CPB) and maintained a price target of $47.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 12:11 pm

DFS

Goldman Sachs analyst Ryan Nash maintains a Buy rating on Discover Financial Services (NYSE:DFS) but has lowered the price target from $128 to $109.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 12:08 pm

CCU

Goldman Sachs has maintained a Neutral rating on United Breweries Co (NYSE:CCU) and lowered the price target from $16.8 to $14.8.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 12:06 pm

AMAT

Goldman Sachs analyst Toshiya Hari maintains a Buy rating on Applied Mat (NASDAQ:AMAT) and raises the price target from $135 to $155.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 12:04 pm

REGN

BMO Capital analyst Evan David Seigerman has maintained an 'Outperform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised the price target from $960 to $985.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 12:02 pm

PANW

Palo Alto Networks has announced Q1 and FY EPS guidance above analyst estimates, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 12:02 pm

PANW

BMO Capital analyst Keith Bachman maintains an 'Outperform' rating on Palo Alto Networks (NASDAQ:PANW) and raises the price target from $235 to $275.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 12:01 pm

SGHT

Over the past 3 months, 6 analysts have published their opinion on Sight Sciences (NASDAQ:SGHT) stock. The company has an average price target of $10.17, a decrease of 25.6% from the previous average price target of $13.67. The ratings include 2 bullish, 1 somewhat bullish, and 3 indifferent.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 12:01 pm

EXP

Over the last quarter, Eagle Materials (NYSE:EXP) has received a majority of bullish ratings from 11 analysts. The average 12-month price target for the company has increased by 14.52% to $209.91, with a high of $230.00 and a low of $176.00.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 12:01 pm

TNDM

Over the past three months, nine analysts have published their opinions on Tandem Diabetes Care (NASDAQ:TNDM) stock. The average price target is $38.89, compared to the current price of $29.17, implying an upside. However, this average represents a 20.63% decrease from the previous average price target of $49.00.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 12:00 pm